These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 2092283

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, von Broen IM, Cammerer U, Hein R, Hoffmann L, Konyar H, Kreuser ED, Selbach J.
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [Abstract] [Full Text] [Related]

  • 3. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, Fett W, Fischer JT, Göbel B.
    Eur J Cancer; 1995 Feb; 31A(2):146-51. PubMed ID: 7718318
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [Abstract] [Full Text] [Related]

  • 5. Current results of a multicenter trial in multiple myeloma.
    Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Glück S, Görg K, Gramatzki M.
    Onkologie; 1986 Jun; 9(3):168-9. PubMed ID: 3528964
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J.
    Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
    [Abstract] [Full Text] [Related]

  • 8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 9. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A.
    J Clin Oncol; 1993 Jun 15; 11(6):1165-71. PubMed ID: 8501503
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C, Sevilla F, Zapatero A, Blanco L, Sabán J, Serrano M, Serrano Ríos M.
    Rev Clin Esp; 1985 May 15; 176(8):392-5. PubMed ID: 3839590
    [No Abstract] [Full Text] [Related]

  • 12. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
    Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA).
    Blood; 2005 Dec 01; 106(12):3755-9. PubMed ID: 16105975
    [Abstract] [Full Text] [Related]

  • 13. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
    Chou T, Tobinai K, Uike N, Asakawa T, Saito I, Fukuda H, Mizoroki F, Ando K, Iida S, Ueda R, Tsukasaki K, Hotta T, Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG), Japan.
    Jpn J Clin Oncol; 2011 Apr 01; 41(4):586-9. PubMed ID: 21247967
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I.
    J Clin Oncol; 1995 Sep 01; 13(9):2354-60. PubMed ID: 7666094
    [Abstract] [Full Text] [Related]

  • 15. [Induction and maintenance therapy in multiple myeloma. Results of a multicenter study].
    Peest D, Deicher H.
    Onkologie; 1988 Feb 01; 11(1):39-43. PubMed ID: 3283624
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ.
    J Clin Oncol; 1986 Aug 01; 4(8):1227-37. PubMed ID: 3525768
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Aug 01; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.